Revolutionizing Molecular Diagnostics: Ireland

In Ireland, strides in genetics and genomics are evident, but routine use of Next-Generation Sequencing (NGS) remains limited despite well-equipped centers and funding. The absence of Molecular Tumor Boards (MTBs) and reimbursement for NGS or liquid biopsy tests pose challenges. Although there’s a moderate understanding of NGS, there’s a shortage of skilled personnel. Clinical guidelines are updated regularly, but ISO accreditation and comprehensive governance in data sharing are lacking. The healthcare workforce shortage impacts service delivery, and while Ireland engages in collaborations, data governance lacks a central controlling body.

For more in-depth insights, refer to the complete factsheet below.

If you like it, share it